Online citations, reference lists, and bibliographies.
Please confirm you are human
(Sign Up for free to never see this)
← Back to Search

HIV/AIDS Infection: The Beginning Of The End For Today's Greatest Pandemic?

F. Gutierrez
Published 2017 · Medicine

Save to my Library
Download PDF
Analyze on Scholarcy
Share
Recently, there have been significant advances in the fight against human immunodeficiency virus, which have increased the hopes of definitively halting its dissemination and of starting the decline of the epidemic it has caused. Transmission of the infection was drastically reduced when infected patients were given antiretroviral treatments, which boosted the diffusion of treatments to middle- and low-income countries. Global therapy coverage has doubled in recent years; meanwhile the incidence of new infections has decreased. Various curative strategies are also actively being investigated, including those aiming to induce cell resistance to the infection through gene therapy and the elimination of latent virus reservoirs. This article reviews the current situation and future developments in terms of controlling the pandemic and, eventually, curing the infection.
This paper references
10.1038/nature11286
Administration of vorinostat disrupts HIV-1 latency in patients on antiretroviral therapy
N. Archin (2012)
10.1001/jamainternmed.2015.4683
Preexposure Prophylaxis for HIV Infection Integrated With Municipal- and Community-Based Sexual Health Services.
A. Liu (2016)
10.1038/nature14411
Viraemia suppressed in HIV-1-infected humans by broadly neutralizing antibody 3BNC117
M. Caskey (2015)
10.1093/cid/civ778
No New HIV Infections With Increasing Use of HIV Preexposure Prophylaxis in a Clinical Practice Setting.
J. E. Volk (2015)
10.1016/S0092-8674(00)80110-5
Homozygous Defect in HIV-1 Coreceptor Accounts for Resistance of Some Multiply-Exposed Individuals to HIV-1 Infection
R. Liu (1996)
10.1016/j.tim.2015.11.003
Reversal of Latency as Part of a Cure for HIV-1.
T. Rasmussen (2016)
10.1056/NEJMOA1602046
Safety and Efficacy of a Dapivirine Vaginal Ring for HIV Prevention in Women.
A. Nel (2016)
10.1056/NEJMOA1506110
Use of a Vaginal Ring Containing Dapivirine for HIV-1 Prevention in Women
Mtn -Aspire Study Team (2016)
10.1056/NEJMoa1108524
Antiretroviral prophylaxis for HIV prevention in heterosexual men and women.
J. Baeten (2012)
10.1038/382722A0
Resistance to HIV-1 infection in Caucasian individuals bearing mutant alleles of the CCR-5 chemokine receptor gene
M. Samson (1996)
10.1097/01.OGX.0000489577.60775.40
Use of a Vaginal Ring Containing Dapivirine for HIV-1 Prevention in Women
J. Baeten (2016)
10.1016/j.coi.2015.05.001
HIV therapeutic vaccines: moving towards a functional cure.
G. Mylvaganam (2015)
10.1126/scitranslmed.aad5752
Virologic effects of broadly neutralizing antibody VRC01 administration during chronic HIV-1 infection
Rebecca M. Lynch (2015)
10.1038/44755
AIDS: Re-emergence of HIV after stopping therapy
T. Chun (1999)
10.1056/NEJMoa1215541
Dolutegravir plus abacavir-lamivudine for the treatment of HIV-1 infection.
S. Walmsley (2013)
Disorders of body fat distribution in HIV-1-infected patients.
S. Moreno (2009)
10.1016/J.IMMUNI.2007.08.010
Human immunodeficiency virus controllers: mechanisms of durable virus control in the absence of antiretroviral therapy.
S. Deeks (2007)
10.1001/jama.2016.5148
Sexual Activity Without Condoms and Risk of HIV Transmission in Serodifferent Couples When the HIV-Positive Partner Is Using Suppressive Antiretroviral Therapy.
A. Rodger (2016)
10.1097/QAD.0b013e32835a1156
Risk, predictors, and mortality associated with non-AIDS events in newly diagnosed HIV-infected patients: role of antiretroviral therapy
M. Masiá (2013)
10.1089/088922204322749567
The CCR5 and CXCR4 coreceptors--central to understanding the transmission and pathogenesis of human immunodeficiency virus type 1 infection.
J. Moore (2004)
10.1016/J.ATHEROSCLEROSIS.2006.09.013
The role of C-reactive protein as a marker for cardiovascular risk associated with antiretroviral therapy in HIV-infected patients.
M. Masiá (2007)
10.1016/S0140-6736(08)61697-9
Universal voluntary HIV testing with immediate antiretroviral therapy as a strategy for elimination of HIV transmission: a mathematical model
R. Granich (2009)
10.1016/S0140-6736(15)00056-2
Pre-exposure prophylaxis to prevent the acquisition of HIV-1 infection (PROUD): effectiveness results from the pilot phase of a pragmatic open-label randomised trial
S. Mccormack (2016)
10.1136/jfprhc-2012-100379
Prevention of HIV-1 infection with early antiretroviral therapy
M. Rayment (2012)
10.1016/S0140-6736(10)60936-1
Association of highly active antiretroviral therapy coverage, population viral load, and yearly new HIV diagnoses in British Columbia, Canada: a population-based study
J. Montaner (2010)
10.2217/FVL.09.70
Establishment and maintenance of HIV latency: model systems and opportunities for intervention.
M. D. Marsden (2010)
10.1016/S1473-3099(14)70847-3
Uptake of pre-exposure prophylaxis, sexual practices, and HIV incidence in men and transgender women who have sex with men: a cohort study.
R. Grant (2014)
The role of HIV and antiretroviral therapy in bone disease.
F. Gutiérrez (2011)
10.1182/blood-2010-09-309591
Evidence for the cure of HIV infection by CCR5Δ32/Δ32 stem cell transplantation.
K. Allers (2011)
10.1056/NEJMoa1110711
Antiretroviral preexposure prophylaxis for heterosexual HIV transmission in Botswana.
M. Thigpen (2012)
10.1056/NEJMoa1600693
Antiretroviral Therapy for the Prevention of HIV-1 Transmission.
M. Cohen (2016)
10.1126/science.1228160
High Coverage of ART Associated with Decline in Risk of HIV Acquisition in Rural KwaZulu-Natal, South Africa
F. Tanser (2013)
10.1371/journal.pone.0000089
Clinical Outcome of HIV-Infected Patients with Sustained Virologic Response to Antiretroviral Therapy: Long-Term Follow-Up of a Multicenter Cohort
F. Gutiérrez (2006)
10.1007/s11904-016-0299-7
Broadly Neutralizing Antibodies for HIV Eradication
K. Stephenson (2016)
10.1038/mtna.2015.10
Engineering Cellular Resistance to HIV-1 Infection In Vivo Using a Dual Therapeutic Lentiviral Vector.
Bryan P. Burke (2015)
10.1038/nm.1972
HIV reservoir size and persistence are driven by T cell survival and homeostatic proliferation
N. Chomont (2009)
10.1056/NEJMoa1300662
Gene editing of CCR5 in autologous CD4 T cells of persons infected with HIV.
P. Tebas (2014)
10.1146/annurev-pathol-011110-130254
Pathogenic mechanisms of HIV disease.
S. Moir (2011)
10.1097/INF.0b013e31826fe968
Low Rates of Mother-to-child Transmission of HIV-1 and Risk Factors for Infection in Spain: 2000–2007
L. Prieto (2012)
10.1056/NEJMoa1506273
On-Demand Preexposure Prophylaxis in Men at High Risk for HIV-1 Infection.
J. Molina (2015)
10.1086/588673
Expanded access to highly active antiretroviral therapy: a potentially powerful strategy to curb the growth of the HIV epidemic.
V. Lima (2008)



This paper is referenced by
Semantic Scholar Logo Some data provided by SemanticScholar